Romano Brothers & Co’s Novavax NVAX Stock Holding History

Romano Brothers & Co’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50	Closed	-$514	–	739
2022 Q4	$514	Buy	+50	New	+$882	﹤0.01%	1017

Other funds holding NVAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Romano Brothers & Co's NVAX Position: Q1 2023 in Review

Romano Brothers & Co sold out of Novavax (NVAX) in Q1 2023, closing a stake of 50 shares — an estimated $514 sold.

Romano Brothers & Co first reported a position in NVAX in Q4 2022 and held it in 1 quarter. The position peaked at $514 in Q4 2022. 222 funds tracked by Wall St. Rank hold NVAX as of Q1 2023.

Romano Brothers & Co reported no remaining Novavax position as of Q1 2023 after selling out during the quarter.
Romano Brothers & Co sold 50 Novavax shares in Q1 2023, an estimated $514.
Romano Brothers & Co first reported a position in Novavax in Q4 2022 and held it in 1 quarter.
Romano Brothers & Co's Novavax position peaked at $514 in Q4 2022.
222 funds tracked by Wall St. Rank held Novavax as of Q1 2023.

Based on Romano Brothers & Co's 13F filing for Q1 2023, filed 13 Apr 2023.